Is In-House Manufacturing The Key To Delivering The World's First Diabetes Vaccine?
Worldwide, nearly 422 million people have diabetes, with 1.6 million deaths directly attributed to this disease each year, according to the World Health Organization.1 This causes an overwhelming burden that is placed on patients, in terms of their health and the cost of medication. Organizations like the CDC and American Diabetes Association spend billions of dollars on diabetes prevention and management. However, without therapies that can target the metabolic abnormalities in diabetic patients, preventing the body’s attack on insulin and even improving its ability to create it, these investments may only become a drop in the ocean.
Diamyd Medical, a Swedish biotech company dedicated to preventing, treating, and curing autoimmune diabetes, is making significant clinical progress with its diabetes vaccine, Diamyd®. Delivering this product to market requires a robust manufacturing process and a facility to consistently execute it. With the increasing constraints on today’s supply chain from the COVID-19 pandemic, drug companies like Diamyd Medical must secure strategies that can ensure product delivery despite the challenges.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.